Cryo-Cell Intl Inc SEC Filings

Cryo-Cell International (CCEL)$4.00 on 11/17/2025, 640 shares at $4.09 on 11/18/2025, and 1,921 shares at a weighted average price of $4.08 on 11/19/2025.

Following these transactions, he directly beneficially owns 846,540 common shares and also reports additional indirect holdings through various entities and family accounts. He further holds several stock option awards, including grants exercisable at prices ranging from $4.30 to $12.27 per share with expirations between 2027 and 2030 and vesting schedules tied to time and, in one case, the stock reaching $25.00 per share.

Cryo-Cell International (CCEL) insider David I. Portnoy (Director, 10% Owner, Chairman, Co-CEO) reported open-market purchases of common stock. He acquired 1,026 shares at $4.18 on 11/10/2025, 2,474 shares at a weighted average price of $4.13 on 11/11/2025, and 2,040 shares at a weighted average price of $4.12 on 11/12/2025. Following these trades, his direct beneficial ownership stands at 842,550 shares.

He also reports derivative holdings, including 280,000 stock options at $12.27 expiring 12/22/2028, which vest immediately if the stock reaches $25 during the seven-year term.

Cryo-Cell International (CCEL) announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company stated that future dividends may or may not be paid, with decisions driven by financial performance, capital requirements, and strategic priorities.

This update signals a pause in cash distributions for Q4 FY2025 and places emphasis on deploying resources based on operating needs and strategic plans. The company’s stance leaves flexibility for future payouts if conditions align with its financial and strategic criteria.

Cryo-Cell International (CCEL) reported insider purchases by Chairman and Co-CEO David I. Portnoy. He acquired 4,666 shares of common stock on 10/31/2025 at $4.45 and 5,000 shares on 11/04/2025 at a weighted average price of $4.40.

Following these transactions, Portnoy beneficially owned 837,010 shares directly. He also reports additional indirect holdings through entities and family accounts, as listed in the filing.

Cryo-Cell International (CCEL) amended its credit facilities with Susser Bank. The Fifth Amendment adds wholly owned subsidiary Celle Corp. as a guarantor and updates key terms of the company’s revolving credit facility and term loan.

The revolving credit facility’s commitment was revised to $8,000,000 and its maturity extended to October 18, 2027. The term loan maturity was extended to July 29, 2032. The amendment also sets revised pricing: Base Rate margins of 4.25% for term loans and 3.75% for revolving loans, Monthly SOFR margins of 3.25% for term loans and 2.75% for revolving loans, and a 0.25% commitment fee.

Existing rate constructs and floors remain in place from the 2022 agreement, with the company able to elect Base Rate or Monthly SOFR-based interest. The changes extend maturities while reducing revolver capacity, and add collateral support via a Security Agreement benefiting the lenders.

Cryo-Cell International (CCEL) filed a Form 4 reporting a director equity award. On 10/21/2025, director Daniel Mizrahi received a grant of stock options to purchase 5,300 shares at $4.35 per share, expiring on 10/21/2035. The options vest at a rate of 1/12 per month commencing on 10/21/2025.

Following the reported transactions, the reporting person directly beneficially owned 30,634 shares of common stock. The filing also lists prior option grants of 5,300 shares each dated 10/20/2021, 10/03/2022, 10/10/2023, and 10/29/2024 with exercise prices of $12.63, $6.50, $4.90, and $5.82, respectively.

Cryo-Cell International (CCEL) director reported a new stock option grant. On 10/21/2025, the director received options for 5,300 shares at an exercise price of $4.35, exercisable on 10/21/2025 and expiring on 10/21/2035. Following the reported transactions, the director directly beneficially owned 57,901 shares of common stock. The filing also lists multiple prior stock option awards with various exercise prices and maturities.

Cryo-Cell International (CCEL) filed its quarterly report, showing stable operations with softer topline. Revenue for the quarter ended August 31, 2025 was $7.83 million versus $8.07 million a year ago, as public banking and product sales remained small. Operating income improved to $1.90 million from $1.39 million on lower cost of sales and SG&A. Net income was $0.75 million ($0.09 diluted EPS) compared with $1.05 million ($0.13) last year.

For the nine months, revenue was $23.72 million versus $23.96 million; net income was $1.39 million ($0.17 diluted EPS) versus $2.26 million ($0.27). Interest expense weighed on results at $0.54 million in the quarter and $1.58 million year-to-date.

Deferred revenue tied to long-term storage contracts rose to $59.58 million ($9.74 million current), supporting future revenue recognition. Cash was $265,207 with $2.96 million in marketable securities. The company reported a stockholders’ deficit of $14.83 million driven by deferred revenue accounting and treasury stock. Debt included a $3.20 million line of credit and $8.39 million term note. As of October 15, 2025, 8,055,150 common shares were outstanding.

The proxy discloses governance and shareholder procedural details for Cryo-Cell International, Inc. It states the Audit Committee charter defines the committees duties, membership rules and relationship with independent auditors and management but does not set director nomination procedures. The document lists exact stockholder nomination and proposal submission requirements, including identity, holdings, arrangements, nominee consents and intent to solicit or appear at the meeting. Beneficial ownership disclosures include Adam Fleishman reporting 279,000 shares held by his trust and 230,000 shares personally, and a Patent and Technology License with Duke University that issued 409,734 shares upon execution. Detailed ownership allocations are provided for David Portnoy and Mark Portnoy (including 401(k), IRA, individual holdings, related-entity holdings and numerous option pools). Multiple stock option vesting schedules and executive post-termination benefits for disability and death (including two times base salary and continued insurance coverage) plus non-compete and non-solicit restrictions are described.